Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
CGC vs ACB vs TLRY vs CRON vs IIPR
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
REIT - Industrial
CGC vs ACB vs TLRY vs CRON vs IIPR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic | REIT - Industrial |
| Market Cap | $122M | $195M | $660M | $981M | $1.62B |
| Revenue (TTM) | $294M | $361M | $1.17B | $193M | $263M |
| Net Income (TTM) | $-327M | $41M | $-2.95B | $-9M | $120M |
| Gross Margin | 22.8% | 62.7% | 28.0% | 32.5% | 60.3% |
| Operating Margin | -24.1% | 13.3% | -266.0% | -1.5% | 46.7% |
| Forward P/E | — | 164.2x | — | 34.3x | 13.2x |
| Total Debt | $348M | $104M | $451M | $2M | $394M |
| Cash & Equiv. | $114M | $184M | $304M | $792M | $48M |
CGC vs ACB vs TLRY vs CRON vs IIPR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Canopy Growth Corpo… (CGC) | 100 | 0.7 | -99.3% |
| Aurora Cannabis Inc. (ACB) | 100 | 2.4 | -97.6% |
| Tilray Brands, Inc. (TLRY) | 100 | 57.5 | -42.5% |
| Cronos Group Inc. (CRON) | 100 | 39.4 | -60.6% |
| Innovative Industri… (IIPR) | 100 | 69.3 | -30.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CGC vs ACB vs TLRY vs CRON vs IIPR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Among these 5 stocks, CGC doesn't own a clear edge in any measured category.
ACB is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 27.0%, EPS growth 102.2%, 3Y rev CAGR 15.8%
- 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2%
TLRY ranks third and is worth considering specifically for momentum.
- +12.1% vs ACB's -25.3%
CRON is the clearest fit if your priority is sleep-well-at-night and defensive.
- Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
- Beta 0.98, current ratio 19.59x
- 64.4% revenue growth vs IIPR's -13.8%
IIPR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- Dividend streak 9 yrs, beta 0.92, yield 13.5%
- 436.4% 10Y total return vs CRON's 14.6%
- Lower P/E (13.2x vs 34.3x)
- 45.6% margin vs TLRY's -252.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 64.4% revenue growth vs IIPR's -13.8% | |
| Value | Lower P/E (13.2x vs 34.3x) | |
| Quality / Margins | 45.6% margin vs TLRY's -252.6% | |
| Stability / Safety | Beta 0.92 vs TLRY's 2.03, lower leverage | |
| Dividends | 13.5% yield; 9-year raise streak; the other 4 pay no meaningful dividend | |
| Momentum (1Y) | +12.1% vs ACB's -25.3% | |
| Efficiency (ROA) | 5.2% ROA vs TLRY's -100.6%, ROIC 0.7% vs -66.2% |
CGC vs ACB vs TLRY vs CRON vs IIPR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
CGC vs ACB vs TLRY vs CRON vs IIPR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IIPR leads in 2 of 6 categories
TLRY leads 2 • CGC leads 0 • ACB leads 0 • CRON leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IIPR leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TLRY is the larger business by revenue, generating $1.2B annually — 6.0x CRON's $193M. IIPR is the more profitable business, keeping 45.6% of every revenue dollar as net income compared to TLRY's -2.5%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $294M | $361M | $1.2B | $193M | $263M |
| EBITDAEarnings before interest/tax | -$32M | $71M | -$3.0B | -$810,000 | $197M |
| Net IncomeAfter-tax profit | -$327M | $41M | -$2.9B | -$9M | $120M |
| Free Cash FlowCash after capex | -$86M | -$31M | -$94M | -$163,766 | $144M |
| Gross MarginGross profit ÷ Revenue | +22.8% | +62.7% | +28.0% | +32.5% | +60.3% |
| Operating MarginEBIT ÷ Revenue | -24.1% | +13.3% | -2.7% | -1.5% | +46.7% |
| Net MarginNet income ÷ Revenue | -111.0% | +11.2% | -2.5% | -4.9% | +45.6% |
| FCF MarginFCF ÷ Revenue | -29.3% | -8.7% | -8.1% | -0.1% | +54.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +20.9% | +6.8% | +3.0% | +2.0% | -3.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.8% | -94.5% | +70.7% | -100.0% | -1.0% |
Valuation Metrics
TLRY leads this category, winning 2 of 5 comparable metrics.
Valuation Metrics
At 14.4x trailing earnings, IIPR trades at a 91% valuation discount to ACB's 164.2x P/E. On an enterprise value basis, ACB's 6.7x EV/EBITDA is more attractive than IIPR's 9.9x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $122M | $195M | $660M | $981M | $1.6B |
| Enterprise ValueMkt cap + debt − cash | $293M | $136M | $806M | $190M | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | -0.28x | 164.21x | -0.17x | — | 14.40x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 34.27x | 13.17x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 3.85x |
| EV / EBITDAEnterprise value multiple | — | 6.73x | — | — | 9.91x |
| Price / SalesMarket cap ÷ Revenue | 0.62x | 0.77x | 0.59x | 5.07x | 6.08x |
| Price / BookPrice ÷ Book value/share | 0.34x | 0.43x | 0.25x | 0.90x | 0.87x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | 9.26x |
Profitability & Efficiency
Evenly matched — ACB and CRON and IIPR each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
ACB delivers a 7.2% return on equity — every $100 of shareholder capital generates $7 in annual profit, vs $-137 for TLRY. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ACB scores 7/9 vs IIPR's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -43.1% | +7.2% | -136.5% | -0.9% | +6.4% |
| ROA (TTM)Return on assets | -29.5% | +5.2% | -100.6% | -0.8% | +5.1% |
| ROICReturn on invested capital | -10.2% | +0.7% | -66.2% | -0.8% | +4.3% |
| ROCEReturn on capital employed | -12.4% | +0.7% | -78.1% | -0.3% | +5.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 7 | 4 | 6 | 4 |
| Debt / EquityFinancial leverage | 0.72x | 0.17x | 0.22x | 0.00x | 0.21x |
| Net DebtTotal debt minus cash | $235M | -$80M | $147M | -$790M | $346M |
| Cash & Equiv.Liquid assets | $114M | $184M | $304M | $792M | $48M |
| Total DebtShort + long-term debt | $348M | $104M | $451M | $2M | $394M |
| Interest CoverageEBIT ÷ Interest expense | -7.79x | 6.27x | -89.43x | — | 6.67x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IIPR five years ago would be worth $4,999 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, TLRY leads with a +1209.3% total return vs ACB's -25.3%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.7% vs CGC's -55.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.0% | -21.0% | -41.8% | -4.8% | +18.3% |
| 1-Year ReturnPast 12 months | -12.4% | -25.3% | +1209.3% | +38.9% | +20.3% |
| 3-Year ReturnCumulative with dividends | -91.4% | -47.2% | +103.6% | +29.1% | +14.1% |
| 5-Year ReturnCumulative with dividends | -99.6% | -96.1% | -65.0% | -66.6% | -50.0% |
| 10-Year ReturnCumulative with dividends | -94.3% | -92.0% | -74.7% | +1457.6% | +436.4% |
| CAGR (3Y)Annualised 3-year return | -55.9% | -19.2% | +26.7% | +8.9% | +4.5% |
Risk & Volatility
IIPR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
IIPR is the less volatile stock with a 0.92 beta — it tends to amplify market swings less than TLRY's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IIPR currently trades 92.2% from its 52-week high vs TLRY's 36.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.90x | 1.81x | 2.03x | 0.98x | 0.92x |
| 52-Week HighHighest price in past year | $2.38 | $6.67 | $15.70 | $3.43 | $61.40 |
| 52-Week LowLowest price in past year | $0.84 | $3.07 | $0.35 | $1.84 | $44.58 |
| % of 52W HighCurrent price vs 52-week peak | +47.5% | +51.4% | +36.1% | +74.9% | +92.2% |
| RSI (14)Momentum oscillator 0–100 | 52.9 | 52.2 | 37.9 | 49.3 | 59.3 |
| Avg Volume (50D)Average daily shares traded | 10.4M | 979K | 4.7M | 1.4M | 303K |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: CGC as "Hold", ACB as "Hold", TLRY as "Hold", CRON as "Hold", IIPR as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -22.3% for IIPR (target: $44). IIPR is the only dividend payer here at 13.46% yield — a key consideration for income-focused portfolios.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Hold | Hold | Hold |
| Price TargetConsensus 12-month target | $14.47 | $5.92 | $10.00 | $2.30 | $44.00 |
| # AnalystsCovering analysts | 26 | 14 | 20 | 15 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | +13.5% |
| Dividend StreakConsecutive years of raises | — | — | — | — | 9 |
| Dividend / ShareAnnual DPS | — | — | — | — | $7.62 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +1.0% | +1.2% |
IIPR leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). TLRY leads in 2 (Valuation Metrics, Total Returns). 1 tied.
CGC vs ACB vs TLRY vs CRON vs IIPR: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CGC or ACB or TLRY or CRON or IIPR a better buy right now?
For growth investors, Cronos Group Inc.
(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). Innovative Industrial Properties, Inc. (IIPR) offers the better valuation at 14. 4x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Canopy Growth Corporation (CGC) a "Hold" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CGC or ACB or TLRY or CRON or IIPR?
On trailing P/E, Innovative Industrial Properties, Inc.
(IIPR) is the cheapest at 14. 4x versus Aurora Cannabis Inc. at 164. 2x. On forward P/E, Innovative Industrial Properties, Inc. is actually cheaper at 13. 2x.
03Which is the better long-term investment — CGC or ACB or TLRY or CRON or IIPR?
Over the past 5 years, Innovative Industrial Properties, Inc.
(IIPR) delivered a total return of -50. 0%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus CGC's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CGC or ACB or TLRY or CRON or IIPR?
By beta (market sensitivity over 5 years), Innovative Industrial Properties, Inc.
(IIPR) is the lower-risk stock at 0. 92β versus Tilray Brands, Inc. 's 2. 03β — meaning TLRY is approximately 121% more volatile than IIPR relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CGC or ACB or TLRY or CRON or IIPR?
By revenue growth (latest reported year), Cronos Group Inc.
(CRON) is pulling ahead at 64. 4% versus -13. 8% for Innovative Industrial Properties, Inc. (IIPR). On earnings-per-share growth, the picture is similar: Aurora Cannabis Inc. grew EPS 102. 2% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, CRON leads at 30. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CGC or ACB or TLRY or CRON or IIPR?
Innovative Industrial Properties, Inc.
(IIPR) is the more profitable company, earning 43. 0% net margin versus -266. 3% for Tilray Brands, Inc. — meaning it keeps 43. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IIPR leads at 46. 7% versus -277. 9% for TLRY. At the gross margin level — before operating expenses — IIPR leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CGC or ACB or TLRY or CRON or IIPR more undervalued right now?
On forward earnings alone, Innovative Industrial Properties, Inc.
(IIPR) trades at 13. 2x forward P/E versus 34. 3x for Cronos Group Inc. — 21. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.
08Which pays a better dividend — CGC or ACB or TLRY or CRON or IIPR?
In this comparison, IIPR (13.
5% yield) pays a dividend. CGC, ACB, TLRY, CRON do not pay a meaningful dividend and should not be held primarily for income.
09Is CGC or ACB or TLRY or CRON or IIPR better for a retirement portfolio?
For long-horizon retirement investors, Cronos Group Inc.
(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, TLRY: -74. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CGC and ACB and TLRY and CRON and IIPR?
These companies operate in different sectors (CGC (Healthcare) and ACB (Healthcare) and TLRY (Healthcare) and CRON (Healthcare) and IIPR (Real Estate)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CGC is a small-cap quality compounder stock; ACB is a small-cap high-growth stock; TLRY is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; IIPR is a small-cap deep-value stock. IIPR pays a dividend while CGC, ACB, TLRY, CRON do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.